Physician profile
Christon Grant
NPI 1750811949
$4,761.33
in general payments reported to CMS, 2019-2025
38 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.79 · 2022: $332 · 2023: $1,095 · 2024: $1,644 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,415.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $747.64 | 2022-2025 | |
| Amgen INC. | $567.62 | 2021-2025 | Prolia, Evenity, Enbrel |
| Astrazeneca Pharmaceuticals LP | $292.94 | 2022-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $276.76 | 2022-2025 | Acthar |
| Ucb, INC. | $272.40 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $271.22 | 2022-2025 | |
| Lilly USA, LLC | $267.26 | 2022-2025 | Taltz, Zepbound, Jardiance |
| Genzyme Corporation | $186.53 | 2023-2025 | |
| Genentech USA, INC. | $169.49 | 2023-2025 | Actemra, Gazyva |
| Glaxosmithkline, LLC. | $159.00 | 2022-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $138.60 | 2024-2025 | Orencia |
| Radius Health, INC. | $134.24 | 2023-2025 | Tymlos |
| Janssen Biotech, INC. | $108.40 | 2025 | Tremfya, Simponi Aria |
| Ani Pharmaceuticals, INC. | $107.75 | 2023-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $103.19 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $90.62 | 2024-2025 | Xyosted |
| Fresenius Kabi USA, LLC | $89.28 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.67 | 2024-2025 | Ofev, Jascayd |
| Tandem Diabetes Care, INC. | $72.23 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $66.72 | 2024-2025 | Crysvita |
| Horizon Therapeutics Plc | $59.36 | 2023 | Krystexxa |
| Sobi, INC | $56.74 | 2024-2025 | |
| Abbott Laboratories | $44.58 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $42.88 | 2023 | |
| Amneal Pharmaceuticals LLC | $38.65 | 2024-2025 | Unithroid |
| Aurinia Pharma U.S., INC. | $36.39 | 2023 | Lupkynis |
| Cequr Corporation | $35.11 | 2024 | Cequr Simplicity |
| Sandoz INC. | $31.89 | 2023-2024 | Hyrimoz |
| Madrigal Pharmaceuticals | $29.54 | 2025 | Rezdiffra |
| Almatica Pharma LLC | $26.93 | 2025 | Teriparatide |
| Sanofi-Aventis U.S. LLC | $25.96 | 2024 | |
| Alvogen INC | $24.34 | 2025 | Teriparatide |
| Xeris Pharmaceuticals, INC. | $23.06 | 2024 | Gvoke Hypopen |
| Medtronic, INC. | $22.91 | 2025 | Minimed 780g |
| Corcept Therapeutics | $21.43 | 2025 | Korlym |
| Organon LLC | $17.67 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $13.95 | 2024 | Baqsimi |
| Bioventus LLC | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christon Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.